Delphine Le Louet
Stock Analyst at Bernstein
(0.37)
# 4,441
Out of 5,000 analysts
180
Total ratings
43.4%
Success rate
-6.5%
Average return
Main Sectors:
Stocks Rated by Delphine Le Louet
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMS: LKFT Lakefront Biotherapeutics NV | Reiterated: Hold | €27.90 | €26.66 | +4.65% | 3 | Sep 1, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €284.00 → €273.00 | €265.30 | +2.90% | 22 | Jul 30, 2026 | |
| ETR: GXI Gerresheimer AG | Reiterated: Hold | €28.70 | €26.18 | +9.63% | 15 | Jul 29, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Reiterated: Buy | €234.00 → €230.00 | €215.80 | +6.58% | 15 | Jul 28, 2026 | |
| SWX: TECN Tecan Group AG | Upgraded: Hold | CHF 165.20 → CHF 156.00 | CHF 228.00 | -31.58% | 2 | Jan 16, 2026 | |
| STO: GETI.B Getinge AB (publ) | Initiated Coverage: Hold | kr 228.00 | kr 243.00 | n/a | 1 | Jun 17, 2025 | |
| EPA: ERF Eurofins Scientific SE | Reiterated: Hold | €52.80 → €53.80 | €77.72 | n/a | 7 | Nov 28, 2024 | |
| EPA: DBV DBV Technologies S.A. | Reiterated: Buy | €5.70 → €3.03 | €2.00 | n/a | 10 | Mar 17, 2024 | |
| SWX: ALC Alcon Inc. | Reiterated: Hold | CHF 77.60 → CHF 72.20 | CHF 53.32 | n/a | 16 | Feb 29, 2024 | |
| EPA: IPN Ipsen S.A. | Reiterated: Buy | €142.00 → €150.40 | €149.10 | n/a | 14 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €20.30 → €13.60 | €2.77 | n/a | 9 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €57.00 → €57.10 | €37.21 | n/a | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €20.10 → €18.95 | €21.46 | n/a | 12 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €186.40 → €189.80 | €144.70 | n/a | 19 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €103.00 → €101.00 | €77.15 | n/a | 15 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $24.55 | n/a | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €579.00 → €612.00 | €209.50 | n/a | 6 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $13 | $11.60 | n/a | 4 | May 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $144 | $82.55 | n/a | 1 | Oct 8, 2020 |
Lakefront Biotherapeutics NV
Sep 1, 2026
Reiterated: Hold
Price Target: €27.90
Current: €26.66
Upside: +4.65%
Sartorius Aktiengesellschaft
Jul 30, 2026
Reiterated: Buy
Price Target: €284.00 → €273.00
Current: €265.30
Upside: +2.90%
Gerresheimer AG
Jul 29, 2026
Reiterated: Hold
Price Target: €28.70
Current: €26.18
Upside: +9.63%
Sartorius Stedim Biotech S.A.
Jul 28, 2026
Reiterated: Buy
Price Target: €234.00 → €230.00
Current: €215.80
Upside: +6.58%
Tecan Group AG
Jan 16, 2026
Upgraded: Hold
Price Target: CHF 165.20 → CHF 156.00
Current: CHF 228.00
Upside: -31.58%
Getinge AB (publ)
Jun 17, 2025
Initiated Coverage: Hold
Price Target: kr 228.00
Current: kr 243.00
Upside: n/a
Eurofins Scientific SE
Nov 28, 2024
Reiterated: Hold
Price Target: €52.80 → €53.80
Current: €77.72
Upside: n/a
DBV Technologies S.A.
Mar 17, 2024
Reiterated: Buy
Price Target: €5.70 → €3.03
Current: €2.00
Upside: n/a
Alcon Inc.
Feb 29, 2024
Reiterated: Hold
Price Target: CHF 77.60 → CHF 72.20
Current: CHF 53.32
Upside: n/a
Ipsen S.A.
Jan 3, 2024
Reiterated: Buy
Price Target: €142.00 → €150.40
Current: €149.10
Upside: n/a
Dec 22, 2023
Reiterated: Buy
Price Target: €20.30 → €13.60
Current: €2.77
Upside: n/a
Nov 13, 2023
Reiterated: Buy
Price Target: €57.00 → €57.10
Current: €37.21
Upside: n/a
Oct 24, 2023
Reiterated: Hold
Price Target: €20.10 → €18.95
Current: €21.46
Upside: n/a
Oct 20, 2023
Upgraded: Buy
Price Target: €186.40 → €189.80
Current: €144.70
Upside: n/a
Sep 29, 2023
Reiterated: Hold
Price Target: €103.00 → €101.00
Current: €77.15
Upside: n/a
Oct 13, 2022
Downgraded: Hold
Price Target: n/a
Current: $24.55
Upside: n/a
Jan 28, 2022
Upgraded: Buy
Price Target: €579.00 → €612.00
Current: €209.50
Upside: n/a
May 4, 2021
Upgraded: Hold
Price Target: $13
Current: $11.60
Upside: n/a
Oct 8, 2020
Upgraded: Hold
Price Target: $144
Current: $82.55
Upside: n/a